The best example is the discovery of IM, the first TKI targeting BCR‐ABL and actually the best example of an antileukaemic compound that revolutionized the treatment of CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.